Join the Pulmonary Embolism group to help and get support from people like you.
Pulmonary Embolism News
Related terms: Pulmonary Emboli
Pulmonary Embolism More Common in Children Than Previously Thought
THURSDAY, May 22, 2025 – Pulmonary embolism (PE) is more common in children than previously thought, according to a study presented at the American Thoracic Society 2025 International Conference,...
Venous Thromboembolism Risk Higher for Certain Hormonal Contraceptives
THURSDAY, Feb. 13, 2025 – Venous thromboembolism (VTE) risk varies across hormonal contraceptives, according to a research letter published online Feb. 10 in the Journal of the American Medical...
Air Pollution Could Be Raising Your Odds for a Blood Clot
FRIDAY, Dec. 13, 2024 – Breathing in smoggy air over time can significantly raise a person's chances for dangerous blood clots, new research shows. “What’s striking from our study is the increase in ...
Higher Ambient Levels of Air Pollutants Linked to Increased VTE Risk
FRIDAY, Dec. 13, 2024 – Higher ambient levels of air pollutants are associated with increased risk of venous thromboembolism (VTE), according to a study published online Dec. 12 in Blood. Pamela...
FDA Medwatch Alert: Eliquis (apixaban) 5 mg tablets: Recall One Lot- Bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets
ISSUE: Bristol-Myers Squibb Company is voluntarily recalling one lot (#HN0063) of Eliquis 5 mg tablets to the consumer level. This lot was distributed nationwide in the U.S. to wholesalers and retail...
FDA Approves Savaysa (edoxaban) to Prevent Embolic Events in Non-Valvular Atrial Fibrillation
January 8, 2015 – The U.S. Food and Drug Administration today approved the anti-clotting drug Savaysa (edoxaban tablets) to reduce the risk of stroke and dangerous blood clots (systemic embolism) in...
FDA Approves Eliquis (apixaban) for the Treatment of Deep Vein Thrombosis and Pulmonary Embolism
Thursday, August 21, 2014 - Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug...
FDA Medwatch Alert: Coumadin (warfarin sodium) for Injection by Bristol-Myers Squibb: Recall - Particulate Matter
ISSUE: Bristol-Myers Squibb Company issued a voluntary recall of six lots of Coumadin for Injection, 5 mg single-use vials in the U.S. Visible particulate matter was found in a small number of ...
FDA Approves Pradaxa for Deep Venous Thrombosis and Pulmonary Embolism
Ridgefield, CT, April 7, 2014 – Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for th...
FDA Expands Use of Xarelto to Treat, Reduce Recurrence of Blood Clots
November 2, 2012 – The U.S. Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to...
Further information
Related condition support groups
Pulmonary Embolism - First Event, Pulmonary Embolism - Recurrent Event